VEGFA and hepatocellular carcinoma: This study evaluated the real-world efficacy and safety of TACE combined with sintilimab (a PD-1 inhibitor) and a bevacizumab biosimilar (an anti-VEGF agent) in 60 patients with unresectable HCC.